



**PRESS RELEASE**

**FOR IMMEDIATE RELEASE**

## **Haitong International Acted as Joint Sponsor for Sipai Health IPO Deal**

**Hong Kong, 23 December 2022** – Haitong International Securities Group Limited ("Haitong International" or "the Group"; 665.HK) has completed an IPO deal in Hong Kong for Sipai Health Technology Co., Ltd. ("Sipai Health"; 0314.HK), acting as Joint Sponsor, Sponsor-Overall Coordinator, Overall Coordinator, Joint Global Coordinator, Joint Bookrunner and Joint Lead Manager.

As the deal sponsor, Haitong International's investment banking team fully managed the entire process. In the initial stage, the team actively communicated with the company's management in choosing an appropriate listing plan and maintained close communication with the company to understand its situation thoroughly and propose the most effective solutions in addressing its main concerns. Meanwhile, the team kept close communication with the regulatory authorities, laying a solid foundation for the deal's successful launch.

With companies rushing to go public at the end of 2022, Haitong International was able to introduce a number of high-quality investors via its sales capabilities and saw an oversubscription of the project. The offer price was determined at HKD 18.6 per share, raising a total of approximately HKD 185 million (assuming the over-allotment option is not exercised). Shares of Sipai Health were successfully listed on the Hong Kong Stock Exchange today, with the highest stock price of HKD 25.4, up 36% from its IPO price.

Sipai Health currently runs three business lines, including Specialty Pharmacy Business, Physician Research Assistance and Health Insurance Services. In terms of 2021 revenue, it operates the largest privately owned specialty pharmacy, with the respective market share of approximately 3.5% and 7.0% in the overall specialty pharmacy market and the privately owned specialty pharmacy market in China; and the largest oncology site management organization ("SMO"), with the respective market share of approximately 3.6% and 5.5% in the overall SMO market and the overall oncology SMO market in China. As of 30 June 2022, amongst its three core business lines, Sipai Health operates 103 specialty pharmacy stores and specialty medicines including 320 innovative oncology drugs and 231 innovative drugs for the treatment of other critical diseases; achieves 100% coverage of 27 provincial specialized oncology hospitals and five national cancer treatment centers following its in-depth experience and professional expertise in assisting clinical trials for oncology Drugs; and serves approximately 23.9 million members enrolled in its health insurance plans through our health service provider network connecting hospitals, general practitioners and specialists in over 150 major cities across China. Tencent, a prominent technology company,



is the largest institutional shareholder of Sipai Health.

- END -

#### **Disclaimer**

We, Haitong International Securities Group Limited ("Haitong International" or "HTI") have prepared this document/presentation ("Document") for information purpose only and for restricted circulation. We have based this Document on our internal information and information available to the public from sources we believe to be reliable. While we have taken all reasonable care in preparing this Document, we do not represent the information contained in this Document is accurate or complete and we accept no responsibility for errors of fact or for any opinion expressed in this Document.

Opinions, projections and estimates reflect our assessments as of the Document date and are subject to change. We have no obligation to notify you or anyone of any such change. You must make your own independent judgment with respect to any matter contained in this Document. Neither we nor any of our affiliates or our respective directors, officers or employees will be responsible for any losses or damages which any person may suffer or incur as a result of relying upon anything stated or omitted from this Document. This Document does not create any legally binding obligations on us and/or our affiliates.

Nothing contained in this Document is intended to constitute legal, tax, securities or investment advice of any product. No information contained in this Document constitutes an offer, or a solicitation to buy or sell any product of any type or to engage in any other transaction. You should not act or refrain from acting on the basis of any content included in this Document without seeking your own professional or investment advice. This disclaimer is available in both English and Chinese, if there is any discrepancy between the two versions, the English version shall apply and prevail.

#### **Haitong International Securities Group Limited**

Haitong International Securities Group Limited ("Haitong International"; Stock Code: 665.HK) is an international financial institution with established presence in Hong Kong and a rapidly expanding network across the globe. It strives to serve as a bridge linking up the Chinese and overseas capital markets. The parent company of Haitong International is Haitong Securities Co. Ltd ("Haitong Securities", Stock Code: 600837.SH; 6837.HK).

Haitong International is well positioned to serve corporate, institutional, as well as high-net worth clients worldwide. Its well-established financial services platform provides a full spectrum of financial offerings including private wealth management, corporate finance, asset management and global markets (key businesses include sales and trading of both equity and fixed income products, prime brokerage and risk management solutions, and research advisory) businesses. Haitong International possesses a sound risk management system that is in line with international standards. The Company has been assigned a "Baa2" long-term issuer rating by Moody's and a "BBB" long-term credit rating by Standard and Poor's. Haitong International is also a high performer in terms of ESG and corporate governance. It has been assigned "A" in ESG rating by MSCI and included in the FTSE4Good Index by FTSE Russell. Haitong International has a global financial servicing network covering the world's major capital markets including Hong Kong, Singapore, New York, London, Tokyo, Mumbai and Sydney, thereby making it a world-class Chinese financial institution with international competitiveness, systemic importance and brand influence.

For further information, please contact:

#### **Haitong International Securities Group Limited**

Judith Yu

Tel: (852) 2213 8570

Email: [judith.x.yu@htisec.com](mailto:judith.x.yu@htisec.com)

Jessica Au

Tel: (852) 2213 8588

Email: [jessica.sk.au@htisec.com](mailto:jessica.sk.au@htisec.com)

Ginny Kung

Tel: (852) 2213 8586

Email: [ginny.wy.kung@htisec.com](mailto:ginny.wy.kung@htisec.com)